Cargando…
The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to infl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841119/ https://www.ncbi.nlm.nih.gov/pubmed/27123112 http://dx.doi.org/10.3892/ol.2016.4402 |
_version_ | 1782428346021314560 |
---|---|
author | ROŽMAN, SAMO NOVAKOVIĆ, SRDJAN GRABNAR, IZTOK CERKOVNIK, PETRA NOVAKOVIĆ, BARBARA JEZERŠEK |
author_facet | ROŽMAN, SAMO NOVAKOVIĆ, SRDJAN GRABNAR, IZTOK CERKOVNIK, PETRA NOVAKOVIĆ, BARBARA JEZERŠEK |
author_sort | ROŽMAN, SAMO |
collection | PubMed |
description | Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to influence rituximab binding to FcγR, thus altering its antitumor effect in indolent lymphomas. In the present study, the impact of FcγRIIa and FcγRIIIa polymorphisms on the survival and response to immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone was evaluated in diffuse large B-cell lymphoma (DLBCL) patients. A total of 29 Slovenian DLBCL patients were studied. Genotyping was conducted for FcγRIIa-27, FcγRIIa-131, FcγRIIIa-48 and FcγRIIIa-158 polymorphisms. The median follow-up time was 29.7 months (range, 9.7–45.4 months). No significant impact of the genotypes was observed on the treatment response, progression-free or overall survival of DLBCL patients. There was a non-significant trend of an improved response to chemotherapy without additional irradiation in patients homozygous for Val at FCγIIIa-158 compared to Phe carriers. The findings of the present study indicate that FcγR polymorphisms have no influence on the survival of DLBCL patients. |
format | Online Article Text |
id | pubmed-4841119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-48411192016-04-27 The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients ROŽMAN, SAMO NOVAKOVIĆ, SRDJAN GRABNAR, IZTOK CERKOVNIK, PETRA NOVAKOVIĆ, BARBARA JEZERŠEK Oncol Lett Articles Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to influence rituximab binding to FcγR, thus altering its antitumor effect in indolent lymphomas. In the present study, the impact of FcγRIIa and FcγRIIIa polymorphisms on the survival and response to immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone was evaluated in diffuse large B-cell lymphoma (DLBCL) patients. A total of 29 Slovenian DLBCL patients were studied. Genotyping was conducted for FcγRIIa-27, FcγRIIa-131, FcγRIIIa-48 and FcγRIIIa-158 polymorphisms. The median follow-up time was 29.7 months (range, 9.7–45.4 months). No significant impact of the genotypes was observed on the treatment response, progression-free or overall survival of DLBCL patients. There was a non-significant trend of an improved response to chemotherapy without additional irradiation in patients homozygous for Val at FCγIIIa-158 compared to Phe carriers. The findings of the present study indicate that FcγR polymorphisms have no influence on the survival of DLBCL patients. D.A. Spandidos 2016-05 2016-04-01 /pmc/articles/PMC4841119/ /pubmed/27123112 http://dx.doi.org/10.3892/ol.2016.4402 Text en Copyright: © Rožman et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles ROŽMAN, SAMO NOVAKOVIĆ, SRDJAN GRABNAR, IZTOK CERKOVNIK, PETRA NOVAKOVIĆ, BARBARA JEZERŠEK The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients |
title | The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients |
title_full | The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients |
title_fullStr | The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients |
title_full_unstemmed | The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients |
title_short | The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients |
title_sort | impact of fcγriia and fcγriiia gene polymorphisms on responses to rchop chemotherapy in diffuse large b-cell lymphoma patients |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841119/ https://www.ncbi.nlm.nih.gov/pubmed/27123112 http://dx.doi.org/10.3892/ol.2016.4402 |
work_keys_str_mv | AT rozmansamo theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT novakovicsrdjan theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT grabnariztok theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT cerkovnikpetra theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT novakovicbarbarajezersek theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT rozmansamo impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT novakovicsrdjan impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT grabnariztok impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT cerkovnikpetra impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients AT novakovicbarbarajezersek impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients |